查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1990214

烧烫伤软膏市场：2026-2032年全球市场预测（按产品类型、活性成分、烧烫伤严重程度、最终用户和分销管道划分）

Burn Ointment Market by Product Type, Active Ingredient, Burn Degree, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，烧烫伤药膏市场价值将达到 12.7 亿美元，到 2026 年将成长到 13.5 亿美元，到 2032 年将达到 20.2 亿美元，复合年增长率为 6.84%。

主要市场统计数据
基准年 2025 12.7亿美元
预计年份：2026年 13.5亿美元
预测年份 2032 20.2亿美元
复合年增长率 (%) 6.84%

权威概述了现代烧伤护理背后的驱动力，重点介绍了以临床优先事项、监管压力和创新为重点的治疗模式。

烧伤治疗已不再局限于简单的伤口敷料，而是涵盖了合理使用抗生素、再生医学的进步以及以患者为中心、优先考虑功能恢復的护理模式。临床医师如今需要在快速上皮化、感染控制和减少疤痕之间取得平衡，而保险公司和采购团队也越来越重视可证明的临床价值。在此背景下，外用製剂、先进敷料和综合护理路径构成了现代烧伤管理策略的核心。

治疗创新、分散式照护和数位化监测如何重塑烧伤管理的临床实践和商业策略？

烧伤治疗领域正经历着一场变革，其驱动力来自于技术进步、护理模式的转变以及对抗生素抗药性日益增长的担忧。新型外用製剂和给药系统强调标靶抗菌作用与组织保护特性的结合，这反映了整个产业从单纯的对症治疗转向积极促进组织再生治疗方法的转变。同时，手术和非手术治疗途径正在融合，从而促进能够同时支持住院治疗和门诊復健的综合产品策略的形成。

促进供应链韧性、来源多元化以及商业和监管机构之间更紧密合作的新关税措施的营运和策略影响。

2025年关税措施的实施给整个国际供应链带来了新的成本压力，促使人们对局部用药产品的采购、生产和分销方式进行策略性重新评估。许多製造商面临进口原材料和成品成本增加的问题，进而影响了临床领域的采购谈判和库存政策。采购团队已采取措施，提高供应商成本结构的透明度，并探索替代采购方式以降低关税风险。

按细分市场分類的临床和商业性需求：揭示配方选择、成分概况、医疗保健环境和分销管道策略如何决定产品的采用和获取。

基于细分市场的洞察揭示了不同产品类型、活性成分、烧烫伤严重程度、终端用户环境和分销管道所带来的不同的治疗和商业性动态，每种情况都需要量身定制的方法。每种剂型——乳膏、凝胶、软膏和喷雾剂——在易用性、伤口停留时间和与绷带的兼容性方面都具有独特的优势。因此，製剂研发人员必须优化流变特性和防腐体系，以适应临床工作流程和看护者的能力。在活性成分方面，芦荟、生长因子、蜂蜜、银奈米颗粒和磺胺嘧啶银的作用机制、安全性考量和实证依据有显着差异，这会影响临床应用和处方集纳入决策。

临床实务法规和供应链能力的区域差异，需要製定本地化的产品和打入市场策略。

区域趋势对临床实践、法律规范和供应策略有显着影响，因此产品开发和市场准入需要采取在地化策略。在美洲，临床网络强调快速获得急诊和健全的医院采购系统，这为那些已被证实能够减少併发症和缩短住院时间的产品创造了机会。相较之下，在欧洲、中东和非洲，不同的管理体制和异质的报销环境则要求采用模组化的市场策略，优先考虑合规性和有针对性的临床伙伴关係。

我们的竞争优势源自于已证实的临床疗效、强大的生产能力和一体化的商业服务，这些都使我们的产品在整个护理过程中发挥了价值。

烧烫伤药膏市场的竞争优势取决于临床证据、生产可靠性和商业性弹性的综合运用。主要企业透过专注于临床检验、完善的品质体係以及能够处理标准配方和特殊配方的灵活生产来脱颖而出。与学术机构和专业烧烫伤治疗部门建立策略合作伙伴关係，可以进一步提高可靠性并加速真实世界临床证据的累积。此外，整合数位化伤口评估工具和护理教育平台的伙伴关係，能够拓展产品价值，使其超越活性成分本身。

为产品领导者提供切实可行的策略措施，以协调临床证据、生产柔软性和通路特定的商业化，从而建立可持续的竞争优势。

产业领导者应采取多管齐下的方法，平衡证据产生、供应链韧性和可操作的商业性实施，将洞察转化为可衡量的成果。首先，优先进行针对特定烧伤程度和护理环境下活性成分对比的临床试验，以产生可用于药品目录纳入和临床指南制定的可操作证据。其次，投资于灵活的生产结构和多元化的供应商，以降低贸易中断和关税波动带来的风险，确保为需要高级治疗的医疗机构和居家照护项目提供稳定的产品供应。

严谨的混合方法，结合临床证据、专家检验和供应链分析，能够产生可操作且可靠的见解。

这些研究结果是基于对同侪审查的临床文献、监管指南和真实世界临床模式的系统性回顾，并辅以对临床医生、采购专家和供应链管理人员的结构化访谈。在整合证据时，优先考虑高品质的随机对照试验、疗效比较研究和临床指南，以确保建议反映共识和新兴的最佳实践。在缺乏可靠试验数据的情况下，分析中纳入了对活性成分作用机制的理解以及经验丰富的烧伤护理人员的实务经验。

透过强调实证产品开发和强大的商业化，我们可以透过综合结论来改善患者疗效和业务绩效。

总之，优化烧伤治疗需要整合临床疗效、营运韧性和市场导向的商业化策略。活性成分和剂型的创新虽然拓展了治疗的可能性，但临床应用取决于可靠的证据、便利的使用方法和值得信赖的供应链。随着治疗逐渐转向门诊和家庭环境，生产者和医疗保健系统必须通力合作，确保产品在传统医院环境之外仍能保持安全、有效和可近性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：烧烫伤药膏市场：依产品类型划分

  • 奶油
  • 凝胶
  • 软膏
  • 喷

第九章：以活性成分分類的烧烫伤软膏市场

  • 芦荟
  • 生长因子
  • 蜂蜜
  • 银奈米粒子
  • 磺胺嘧啶银

第十章：依烧烫伤严重程度分類的烧烫伤药膏市场

  • 一度烧伤
  • 二度烧伤
  • 三度烧伤

第十一章：烧烫伤药膏市场：以最终用户划分

  • 门诊手术中心
  • 烧伤中心
  • 居家照护
  • 医院和诊所

第十二章：烧烫伤药膏市场：依分销管道划分

  • 医院药房
  • 网路商店
  • 零售药房

第十三章：烧烫伤药膏市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：烧烫伤膏市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：烧烫伤药膏市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国烧烫伤药膏市场

第十七章：中国烧烫伤药膏市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 3M Company
  • Advancis Medical
  • B. Braun SE
  • Cardinal Health, Inc.
  • Cipla Limited
  • Coloplast A/S
  • ConvaTec Group PLC
  • DeRoyal Industries Inc.
  • Dr. Morepen
  • Gentell
  • GlaxoSmithKline PLC
  • Hollister Incorporated
  • Intergra LifeSciences
  • Johnson & Johnson Services, Inc.
  • Mankind Pharma Ltd.
  • Maxingvest AG
  • McKesson Corporation
  • Medline Industries, LP
  • Milliken & Company
  • Molnlycke Health Care AB
  • Otsuka Pharmaceutical Co., Ltd.
  • Paul Hartmann AG
  • Perrigo Company PLC
  • Pfizer Inc.
  • Smith & Nephew PLC
  • Sun Pharmaceutical Industries Ltd.
  • Trio Lifescience Pvt. Ltd.
Product Code: MRR-99555D55052F

The Burn Ointment Market was valued at USD 1.27 billion in 2025 and is projected to grow to USD 1.35 billion in 2026, with a CAGR of 6.84%, reaching USD 2.02 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.27 billion
Estimated Year [2026] USD 1.35 billion
Forecast Year [2032] USD 2.02 billion
CAGR (%) 6.84%

An authoritative overview of contemporary burn care drivers highlighting clinical priorities regulatory pressures and innovation-focused treatment paradigms

Burn treatment has evolved beyond simple wound coverage to encompass antimicrobial stewardship, regenerative medicine advances, and patient-centered care models that prioritize functional recovery. Clinicians now balance rapid re-epithelialization with infection control and scar mitigation, while payers and procurement teams increasingly demand demonstrable clinical value. Against this backdrop, topical formulations, advanced dressings, and integrated care pathways constitute the core of modern burn management strategies.

In parallel, innovation in active ingredients and delivery formats has expanded therapeutic options. Manufacturers and clinicians are integrating biologically active compounds, silver-based antimicrobials, and naturally derived agents into products that aim to reduce healing time and minimize complications. As a result, decision-makers must weigh clinical efficacy, safety profiles, and supply continuity when selecting products for acute care centers, ambulatory surgical settings, and home-based recovery programs. Furthermore, regulatory scrutiny and evolving reimbursement dynamics are shaping product development and commercialization strategies, creating both constraints and opportunities for stakeholders seeking to differentiate on clinical evidence and practical utility.

Consequently, strategic planning for burn care requires a holistic view that reconciles clinical priorities, procurement realities, and emerging scientific evidence to ensure interventions deliver measurable improvements in patient outcomes and system-level efficiencies.

How therapeutic innovation decentralization of care and digital-enabled monitoring are reshaping clinical practice and commercial strategies in burn management

The burn care landscape is undergoing transformative shifts driven by technological advances, changing care delivery models, and heightened focus on antimicrobial resistance. New topical agents and delivery systems emphasize targeted antimicrobial activity combined with tissue-preserving properties, reflecting an industry-wide pivot from purely symptomatic care to therapies that actively support regeneration. At the same time, surgical and non-surgical management pathways are converging, encouraging integrated product strategies that can support both inpatient procedures and outpatient rehabilitation.

Meanwhile, care delivery is decentralizing as many interventions migrate from tertiary burn centers to ambulatory surgical centers and homecare settings. This transition stresses the need for formulations that are easy to apply, stable under variable storage conditions, and safe for non-specialist caregivers. Simultaneously, digital health tools and telemedicine consultations are augmenting clinical oversight, enabling remote monitoring of wound healing and reducing unnecessary clinic visits. These shifts create new expectations for manufacturers to provide not only effective products but also education, adherence support, and digital resources that facilitate remote care.

Taken together, these trends drive a more patient-centric, cost-aware, and evidence-driven market environment where agility, cross-functional collaboration, and a clear value proposition determine commercial success.

The operational and strategic consequences of new tariff measures driving supply chain resilience sourcing diversification and closer commercial-regulatory collaboration

The implementation of tariff measures in 2025 enforced new cost pressures across international supply chains and prompted a strategic reassessment of sourcing, manufacturing, and distribution practices for medical topical agents. Many manufacturers faced increased landed costs for imported raw materials and finished goods, which in turn affected procurement negotiations and inventory policies across clinical settings. Procurement teams responded by seeking greater transparency in supplier cost structures and by exploring alternative sourcing arrangements that reduce tariff exposure.

Consequently, supply chain resilience became a priority, with manufacturers accelerating qualification of secondary suppliers, enlarging safety stocks for critical inputs, and evaluating nearshoring options to mitigate future trade disruptions. At the same time, regulatory compliance and customs administration complexities increased transaction lead times, particularly for specialty active ingredients that require stringent handling. These operational frictions incentivized stronger supplier partnerships and more frequent cross-functional planning between commercial, regulatory, and operations teams.

Ultimately, the cumulative impact of tariff changes reinforced the importance of flexible manufacturing footprints and diversified procurement strategies. Stakeholders that proactively redesigned supply chains and negotiated value-based contracts were better positioned to preserve clinical access and maintain commercial momentum despite cost headwinds.

Segment-specific clinical and commercial imperatives exposing how formulation choices ingredient profiles care settings and channel strategies determine adoption and access

Segmentation-driven insight reveals distinct therapeutic and commercial dynamics across product types, active ingredients, burn degrees, end-user settings, and distribution channels that require tailored approaches. Cream, gel, ointment, and spray formats each present unique advantages related to ease of application, residence time on the wound, and compatibility with dressings; consequently, formulators must optimize rheology and preservative systems to align with clinical workflows and caregiver capabilities. In terms of active agents, aloe vera, growth factors, honey, silver nanoparticles, and silver sulfadiazine differ considerably in mechanism of action, safety considerations, and evidence base, which impacts clinical adoption and formulary decisions.

Burn degree stratification is clinically consequential: first degree, second degree, and third degree injuries demand different therapeutic priorities, ranging from symptomatic relief and infection prophylaxis to advanced regenerative interventions and surgical adjuncts. End-user segments such as ambulatory surgical centers, burn centers, homecare environments, and hospitals and clinics impose varied specifications for product robustness, packaging, and instructional support. Distribution channels further influence product positioning and access; hospital pharmacies, online stores, and retail pharmacies each require distinct commercialization strategies, pricing models, and regulatory documentation to satisfy procurement and consumer expectations.

Therefore, companies must align formulation strategy, clinical evidence generation, and channel management with the nuances of each segment to optimize uptake and ensure products meet the practical needs of clinicians and caregivers across diverse care settings.

How geographic variations in clinical practice regulation and supply chain capabilities necessitate regionally tailored product and market entry strategies

Regional dynamics exert a pronounced influence on clinical practice, regulatory frameworks, and supply strategies, necessitating geographically informed approaches to product development and market entry. In the Americas, clinical networks emphasize rapid access to acute care and robust hospital procurement systems, which create opportunities for products demonstrated to reduce complications and shorten facility stays. Conversely, in Europe, Middle East & Africa, varying regulatory regimes and heterogeneous reimbursement environments encourage modular market strategies that prioritize regulatory alignment and targeted clinical partnerships.

Asia-Pacific presents a diverse mix of advanced tertiary centers and expanding community healthcare capacity, alongside strong manufacturing bases for active ingredients and finished goods. This region often balances high-volume procurement needs with localized clinical preferences and growing demand for both advanced antimicrobials and cost-effective natural alternatives. Across these geographies, differences in patient demographics, scar prevention priorities, and healthcare delivery models shape product acceptance and required evidence packages. Consequently, stakeholders must calibrate clinical trial designs, regulatory submissions, and go-to-market tactics to reflect regional practice patterns and procurement expectations.

In sum, nuanced regional strategies that acknowledge regulatory complexity, supply chain realities, and local clinical priorities yield better patient outcomes and enhance commercial viability across global footprints.

Competitive advantage stems from clinical validation manufacturing resilience and integrated commercial services that extend product value across care pathways

Competitive positioning in the burn ointment arena depends on a blend of clinical evidence, manufacturing reliability, and commercial agility. Leading companies differentiate through focused investment in clinical validation, robust quality systems, and agile manufacturing that accommodates both standard and specialized formulations. Strategic collaborations with academic centers and specialized burn units further strengthen credibility and accelerate real-world evidence generation. In addition, partnerships that integrate digital wound assessment tools or nurse education platforms amplify product value beyond the active compound alone.

Operational excellence is equally important; firms that maintain diversified sourcing and responsive production capacity reduce supply risk and support sustained clinical adoption. Commercially, companies that offer comprehensive supplier services-ranging from training for clinicians to patient education and adherence support-achieve deeper penetration across hospitals, ambulatory surgical centers, and homecare channels. Similarly, flexibility in packaging sizes and formats addresses the varying needs of institutional buyers and retail consumers, improving inventory turnover and lowering waste.

By combining rigorous clinical programs with resilient operations and value-added services, organizations can secure a defensible market position and create pathways for long-term growth despite intensifying competition and evolving care models.

Practical strategic measures for product leaders to align clinical evidence manufacturing flexibility and channel-specific commercialization for sustainable advantage

Industry leaders should adopt a multi-pronged approach that balances evidence generation, supply chain resilience, and pragmatic commercial execution to convert insights into measurable outcomes. First, prioritize targeted clinical studies that compare active ingredients in the contexts of specific burn degrees and care settings to generate actionable evidence for formulary inclusion and clinical guidelines. Second, invest in flexible manufacturing and supplier diversification to reduce exposure to trade disruptions and tariff volatility, thereby safeguarding product availability for high-acuity centers and homecare programs.

Third, develop differentiated go-to-market models that account for channel-specific needs, including hospital pharmacy purchasing behaviors and consumer purchasing via online stores and retail pharmacies. Fourth, integrate clinician education and digital support tools to facilitate appropriate product usage in ambulatory and homecare environments, which will improve adherence and clinical outcomes. Fifth, pursue regionally tailored regulatory strategies that reflect local practice patterns and reimbursement pathways, enabling faster adoption in diverse geographies while ensuring compliance.

Taken together, these actions create a coherent strategy that aligns clinical credibility with operational sturdiness and commercial relevance, positioning companies to capture value while improving patient care.

A rigorous mixed-methods approach combining clinical evidence synthesis expert validation and supply chain analysis to produce actionable and reliable insights

The research underpinning these insights combined a systematic review of peer-reviewed clinical literature, regulatory guidance, and real-world practice patterns, supplemented by structured interviews with clinicians, procurement specialists, and supply chain managers. Evidence synthesis prioritized high-quality randomized trials, comparative effectiveness studies, and clinical guidelines to ensure recommendations reflect consensus and emerging best practice. Where robust trial data were limited, the analysis incorporated mechanistic understanding of active ingredients and practical considerations from experienced burn care providers.

In addition, the study assessed supply chain and policy developments by reviewing tariff schedules, customs processes, and manufacturing capacity reports to evaluate operational implications. Cross-validation occurred through expert panels and clinician workshops that evaluated the practical applicability of recommendations across different care settings. Throughout, the methodology emphasized triangulation of sources to mitigate bias and ensure findings are actionable for commercial and clinical stakeholders. Finally, ethical considerations and patient safety remained central to evaluating therapeutic options, with attention to adverse event profiles and safety monitoring requirements necessary for clinical deployment.

Integrated conclusions that emphasize evidence-led product development and resilient commercialization to improve patient outcomes and business performance

In conclusion, optimizing burn care requires integrated strategies that marry clinical efficacy with operational resilience and market-aware commercialization. Innovations in active ingredients and delivery formats are expanding therapeutic possibilities, but clinical adoption depends on credible evidence, practical usability, and dependable supply chains. As care shifts toward ambulatory and home-based settings, manufacturers and health systems must collaborate to ensure products are safe, effective, and accessible outside traditional hospital environments.

Moreover, trade dynamics and regulatory variation underscore the need for flexible sourcing and region-specific planning. Organizations that proactively invest in diverse supplier networks, targeted clinical programs, and tailored channel strategies will be better positioned to navigate uncertainty while delivering measurable improvements in patient outcomes. Ultimately, the intersection of science, logistics, and market intelligence will determine which products achieve lasting clinical impact and commercial success. Stakeholders that act decisively on these integrated imperatives can drive better care for patients with burn injuries while creating sustainable value for their organizations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Burn Ointment Market, by Product Type

  • 8.1. Cream
  • 8.2. Gel
  • 8.3. Ointment
  • 8.4. Spray

9. Burn Ointment Market, by Active Ingredient

  • 9.1. Aloe Vera
  • 9.2. Growth Factors
  • 9.3. Honey
  • 9.4. Silver Nanoparticles
  • 9.5. Silver Sulfadiazine

10. Burn Ointment Market, by Burn Degree

  • 10.1. First Degree Burns
  • 10.2. Second Degree Burns
  • 10.3. Third Degree Burns

11. Burn Ointment Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Burn Centers
  • 11.3. Homecare
  • 11.4. Hospitals Clinics

12. Burn Ointment Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Stores
  • 12.3. Retail Pharmacies

13. Burn Ointment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Burn Ointment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Burn Ointment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Burn Ointment Market

17. China Burn Ointment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. 3M Company
  • 18.6. Advancis Medical
  • 18.7. B. Braun SE
  • 18.8. Cardinal Health, Inc.
  • 18.9. Cipla Limited
  • 18.10. Coloplast A/S
  • 18.11. ConvaTec Group PLC
  • 18.12. DeRoyal Industries Inc.
  • 18.13. Dr. Morepen
  • 18.14. Gentell
  • 18.15. GlaxoSmithKline PLC
  • 18.16. Hollister Incorporated
  • 18.17. Intergra LifeSciences
  • 18.18. Johnson & Johnson Services, Inc.
  • 18.19. Mankind Pharma Ltd.
  • 18.20. Maxingvest AG
  • 18.21. McKesson Corporation
  • 18.22. Medline Industries, LP
  • 18.23. Milliken & Company
  • 18.24. Molnlycke Health Care AB
  • 18.25. Otsuka Pharmaceutical Co., Ltd.
  • 18.26. Paul Hartmann AG
  • 18.27. Perrigo Company PLC
  • 18.28. Pfizer Inc.
  • 18.29. Smith & Nephew PLC
  • 18.30. Sun Pharmaceutical Industries Ltd.
  • 18.31. Trio Lifescience Pvt. Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BURN OINTMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BURN OINTMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BURN OINTMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BURN OINTMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BURN OINTMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BURN OINTMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BURN OINTMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BURN OINTMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BURN OINTMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BURN OINTMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BURN OINTMENT MARKET SIZE, BY CREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BURN OINTMENT MARKET SIZE, BY CREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BURN OINTMENT MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BURN OINTMENT MARKET SIZE, BY GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BURN OINTMENT MARKET SIZE, BY GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BURN OINTMENT MARKET SIZE, BY GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BURN OINTMENT MARKET SIZE, BY OINTMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BURN OINTMENT MARKET SIZE, BY OINTMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BURN OINTMENT MARKET SIZE, BY OINTMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BURN OINTMENT MARKET SIZE, BY SPRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BURN OINTMENT MARKET SIZE, BY SPRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BURN OINTMENT MARKET SIZE, BY SPRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BURN OINTMENT MARKET SIZE, BY ALOE VERA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BURN OINTMENT MARKET SIZE, BY ALOE VERA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BURN OINTMENT MARKET SIZE, BY ALOE VERA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BURN OINTMENT MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BURN OINTMENT MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BURN OINTMENT MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BURN OINTMENT MARKET SIZE, BY HONEY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BURN OINTMENT MARKET SIZE, BY HONEY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BURN OINTMENT MARKET SIZE, BY HONEY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BURN OINTMENT MARKET SIZE, BY SILVER NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BURN OINTMENT MARKET SIZE, BY SILVER NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BURN OINTMENT MARKET SIZE, BY SILVER NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BURN OINTMENT MARKET SIZE, BY SILVER SULFADIAZINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BURN OINTMENT MARKET SIZE, BY SILVER SULFADIAZINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BURN OINTMENT MARKET SIZE, BY SILVER SULFADIAZINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BURN OINTMENT MARKET SIZE, BY FIRST DEGREE BURNS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BURN OINTMENT MARKET SIZE, BY FIRST DEGREE BURNS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BURN OINTMENT MARKET SIZE, BY FIRST DEGREE BURNS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BURN OINTMENT MARKET SIZE, BY SECOND DEGREE BURNS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BURN OINTMENT MARKET SIZE, BY SECOND DEGREE BURNS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BURN OINTMENT MARKET SIZE, BY SECOND DEGREE BURNS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BURN OINTMENT MARKET SIZE, BY THIRD DEGREE BURNS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BURN OINTMENT MARKET SIZE, BY THIRD DEGREE BURNS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BURN OINTMENT MARKET SIZE, BY THIRD DEGREE BURNS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BURN OINTMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BURN OINTMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BURN OINTMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BURN OINTMENT MARKET SIZE, BY BURN CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BURN OINTMENT MARKET SIZE, BY BURN CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BURN OINTMENT MARKET SIZE, BY BURN CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BURN OINTMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BURN OINTMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BURN OINTMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BURN OINTMENT MARKET SIZE, BY HOSPITALS CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BURN OINTMENT MARKET SIZE, BY HOSPITALS CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BURN OINTMENT MARKET SIZE, BY HOSPITALS CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BURN OINTMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BURN OINTMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BURN OINTMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BURN OINTMENT MARKET SIZE, BY ONLINE STORES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BURN OINTMENT MARKET SIZE, BY ONLINE STORES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BURN OINTMENT MARKET SIZE, BY ONLINE STORES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BURN OINTMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BURN OINTMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BURN OINTMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BURN OINTMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS BURN OINTMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA BURN OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA BURN OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA BURN OINTMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE BURN OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST BURN OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA BURN OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC BURN OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BURN OINTMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN BURN OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. GCC BURN OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GCC BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. GCC BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 123. GCC BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 124. GCC BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GCC BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION BURN OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS BURN OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. G7 BURN OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. G7 BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. G7 BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 141. G7 BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 142. G7 BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. G7 BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. NATO BURN OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. NATO BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NATO BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 147. NATO BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. NATO BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL BURN OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES BURN OINTMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA BURN OINTMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)